CN117015530A - 尿石素衍生物及其使用方法 - Google Patents

尿石素衍生物及其使用方法 Download PDF

Info

Publication number
CN117015530A
CN117015530A CN202280022588.3A CN202280022588A CN117015530A CN 117015530 A CN117015530 A CN 117015530A CN 202280022588 A CN202280022588 A CN 202280022588A CN 117015530 A CN117015530 A CN 117015530A
Authority
CN
China
Prior art keywords
alkyl
compound
cycloalkyl
heterocycloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022588.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·L·林施
P·安德鲁斯
J·M·萨顿
E·M·苏厄德
J·D·奈特
I·林尼
P·C·森亨
S·欧穆奇
F·博菲尔斯
T·C·费萨德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vandelia Ag
Original Assignee
Vandelia Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vandelia Ag filed Critical Vandelia Ag
Publication of CN117015530A publication Critical patent/CN117015530A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280022588.3A 2021-01-27 2022-01-27 尿石素衍生物及其使用方法 Pending CN117015530A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142333P 2021-01-27 2021-01-27
US63/142333 2021-01-27
PCT/IB2022/000049 WO2022162471A1 (en) 2021-01-27 2022-01-27 Urolithin derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
CN117015530A true CN117015530A (zh) 2023-11-07

Family

ID=80595402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022588.3A Pending CN117015530A (zh) 2021-01-27 2022-01-27 尿石素衍生物及其使用方法

Country Status (11)

Country Link
US (4) US11820751B2 (https=)
EP (1) EP4284781A1 (https=)
JP (1) JP2024503753A (https=)
KR (1) KR20230153533A (https=)
CN (1) CN117015530A (https=)
AU (1) AU2022212883A1 (https=)
BR (1) BR112023014973A2 (https=)
CA (1) CA3206062A1 (https=)
IL (1) IL304680A (https=)
MX (1) MX2023008677A (https=)
WO (1) WO2022162471A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116670144A (zh) * 2020-12-31 2023-08-29 南京再明医药有限公司 三环类化合物及用途
CN119504692A (zh) * 2024-11-21 2025-02-25 常州大学 磷酸二酯酶2抑制剂的3,8-二羟基-6H-苯并[c]色烯-6-酮类8位羟基醚化衍生物及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
WO2023228994A1 (ja) * 2022-05-25 2023-11-30 株式会社ダイセル Ｓｉｒｔ３遺伝子発現増強用組成物
US20240139149A1 (en) * 2022-07-27 2024-05-02 Vandria Sa Therapeutic uses of urolithin derivatives
CN119948002A (zh) * 2022-07-27 2025-05-06 范徳利亚股份公司 尿石素衍生物和治疗用途
WO2024119140A1 (en) 2022-12-01 2024-06-06 Massachusetts Institute Of Technology Cleavable comonomer strategy for accelerating removal of gel nail polish
EP4712958A2 (en) * 2023-05-18 2026-03-25 Vandria SA Use of urolithin derivatives in the treatment of amyotrophic lateral sclerosis
CN116715649A (zh) * 2023-06-07 2023-09-08 武汉大学人民医院（湖北省人民医院） 肝癌药四碳链环己亚胺甲基尿石素a及其制备方法和应用
CN116715650A (zh) * 2023-06-07 2023-09-08 武汉大学人民医院（湖北省人民医院） 尿石素类衍生物及其制备方法和应用
CN119661547A (zh) * 2023-09-20 2025-03-21 科辉智药(深圳)新药研究中心有限公司 作为sarm1酶活性抑制剂的三环吡啶类化合物及其应用
CN121318904A (zh) * 2024-07-12 2026-01-13 深圳市翰林生物医药科技有限公司 用于改善线粒体功能、防治衰老和线粒体相关疾病的化合物及其制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353717A (zh) * 1999-05-04 2002-06-12 莱加制药公司 四环黄体酮受体调节剂化合物及其方法
WO2004076438A2 (de) * 2003-02-25 2004-09-10 Merck Patent Gmbh Benzochromenderivate
WO2007075884A2 (en) * 2005-12-21 2007-07-05 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CN103370310A (zh) * 2011-02-09 2013-10-23 参天制药株式会社 3-羟基-6H-苯并[c]色烯-6-酮衍生物及其制备方法
US20180256538A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Method for improving mitophagy in subjects
WO2019222146A1 (en) * 2018-05-15 2019-11-21 University Of Louisville Research Foundation, Inc. Urolithin a and derivatives thereof for use in therapy
CN110862368A (zh) * 2019-11-25 2020-03-06 浙江工业大学 一种苯并香豆素类化合物的光催化氧化合成方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821201A (en) * 1971-08-09 1974-06-28 Merck & Co Inc Dibenzo(c,e)azepin-5-ones
US4463001A (en) 1980-10-20 1984-07-31 Farmitalia Carlo Erba S.P.A. 6-Substituted 6H-dibenzo[b,d]pyran derivatives and process for their preparation
JPH02304080A (ja) 1989-05-17 1990-12-17 Toyo Pharma- Kk ６Ｈ―ジベンゾ［ｂ，ｄ］ピラン―６―オン誘導体，その製法及び用途
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
JPH05214334A (ja) 1992-02-05 1993-08-24 Konica Corp 有機薄膜エレクトロルミネッセンス素子
JPH06234753A (ja) 1993-02-10 1994-08-23 Meiji Seika Kaisha Ltd イソオキサゾール化合物およびその塩
JPH07188215A (ja) 1993-12-28 1995-07-25 Meiji Seika Kaisha Ltd アゾール誘導体及びその塩
JPH1172941A (ja) 1997-08-29 1999-03-16 Canon Inc 電子写真感光体
WO1999014217A1 (en) 1997-09-17 1999-03-25 Merck & Co., Inc. Aryloxymethyl carbapenem antibacterials
US6284753B2 (en) 1998-06-02 2001-09-04 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
AU2002215737A1 (en) 2000-12-05 2002-06-18 Chemokine Therapeutics Corporation Tricyclic therapeutics for chemokine mediated diseases
AU2002251949A1 (en) 2001-02-16 2002-09-04 Bristol-Myers Squibb Company Compounds having retinoid-like activity
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
EP1652841A1 (en) 2004-04-30 2006-05-03 Switch Biotech Aktiengesellschaft Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes
BRPI0708318A2 (pt) 2006-02-28 2011-05-24 Paloma Pharmaceuticals, Inc. composições e uso de compostos para tratar doenças caracterizadas por proliferação celular e angiogênese
US20090118135A1 (en) * 2007-06-08 2009-05-07 The Burnham Institute Methods and compounds for regulating apoptosis
EP2214670A2 (en) 2007-11-02 2010-08-11 Taiga Biotechnologies, Inc. Compounds for treating abnormal cellular proliferation
CN101654401B (zh) 2008-08-18 2013-06-05 中国人民解放军军事医学科学院毒物药物研究所 不对称联苯类化合物、含有它的药物组合物及其用途
DE102009022309A1 (de) 2009-05-22 2010-11-25 Merck Patent Gmbh Flüssigkristallanzeige
JP5385686B2 (ja) * 2009-06-05 2014-01-08 サントリーホールディングス株式会社 血小板凝集抑制剤
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
JPWO2011093483A1 (ja) 2010-02-01 2013-06-06 国立大学法人 鹿児島大学 Ｃ型肝炎治療剤
JP6054301B2 (ja) 2010-12-23 2017-01-11 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
EP2729007A1 (de) 2011-07-04 2014-05-14 Bayer Intellectual Property GmbH Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
WO2013041461A1 (en) 2011-09-22 2013-03-28 Msd Oss B.V. Fsh receptor antagonists
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
JP2014139161A (ja) * 2012-12-20 2014-07-31 Santen Pharmaceut Co Ltd １，２−ジヒドロキノリン合成中間体の製造方法
WO2014111580A1 (en) 2013-01-18 2014-07-24 Procell Sprl Urolithin b for muscle growth
EP2958906A1 (en) 2013-02-21 2015-12-30 Nobel Ilaç Sanayii Ve Ticaret A.S. 3-substituted-6h-benzo[c]chromen-6-ones and 3-substituted-7,8,9,10-tetrahydro-6h-benzo[c]chromen-6-ones against senile dementia
CN104231023B (zh) 2013-06-06 2019-02-05 南京汇诚制药有限公司 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用
KR20160075766A (ko) 2013-10-29 2016-06-29 메디비르 아베 퀴나졸린계 호흡기 세포융합 바이러스 억제제
EP3663287B1 (en) 2013-12-23 2023-09-20 Amazentis SA Process scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
CN103772228B (zh) 2014-01-16 2016-01-20 华东理工大学 联苯双酰胺类化合物及其制备和用途
WO2015140799A1 (en) 2014-03-18 2015-09-24 Carmel-Haifa University Economic Corp. Ltd Methods for improving cognitive function via modulation of quinone reductase 2
WO2015154047A1 (en) * 2014-04-03 2015-10-08 Restorgenex Corporation Novel methods
JP2016162983A (ja) 2015-03-04 2016-09-05 ダイキン工業株式会社 エッチング処理用組成物及びエッチング処理方法
CN105085463B (zh) * 2015-08-25 2017-06-16 浙江医学高等专科学校 一种微波快速制备联芳基七元内酯的方法
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
AU2016375177B2 (en) 2015-12-24 2022-09-01 Amazentis Sa Compositions comprising nicotinamide riboside and a urolithin
WO2018073321A1 (en) 2016-10-18 2018-04-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis
WO2018119208A1 (en) 2016-12-22 2018-06-28 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
CN106632214B (zh) 2016-12-28 2019-01-25 西北大学 一种大麻酚类化合物的合成方法
CN108530480B (zh) 2017-03-06 2022-06-28 中国科学院上海药物研究所 Gpr84受体拮抗剂及其应用
CN106928173B (zh) * 2017-03-07 2019-04-16 中国科学院新疆理化技术研究所 薰衣草中的酚酸类化合物及其制备方法和用途
JP7761372B2 (ja) 2017-03-08 2025-10-28 アマゼンティス エスアー 対象におけるマイトファジーを改善するための方法
US20180256471A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods
US12171755B2 (en) 2017-10-25 2024-12-24 Children's Medical Center Corporation PAPD5 inhibitors and methods of use thereof
CN109761902B (zh) 2017-11-09 2022-06-10 四川大学 6-菲啶酮衍生物及其制备方法和用途
DE102017126343A1 (de) 2017-11-10 2019-05-16 Peri Gmbh Bewehrung von 3D-gedruckten Betonkörpern
AU2019227733B2 (en) 2018-02-27 2024-08-01 Amazentis Sa Process-scale synthesis of urolithin A
WO2019205854A1 (zh) 2018-04-27 2019-10-31 四川大学 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与用途
WO2019211294A1 (en) 2018-04-30 2019-11-07 Amazentis Sa Urolithin a as immune enhancer
PL245399B1 (pl) * 2018-11-29 2024-07-15 Univ Warszawski Medyczny Kompozycja farmaceutyczna zawierająca urolitynę A lub jej pochodną do zastosowania zewnętrznego miejscowego w leczeniu, hamowaniu i zapobieganiu chorobom skóry i błon śluzowych o podłożu zapalnym
WO2020124206A1 (en) 2018-12-18 2020-06-25 University Of Manitoba Metal complexes, methods of making the same, and uses thereof
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
CN111072850B (zh) * 2019-12-18 2022-02-15 湖北大学 荧光分子单体及其制备方法、聚集诱导发光水凝胶及其制备方法和应用
CN112778140B (zh) 2020-12-29 2023-01-03 宁波博雅聚力新材料科技有限公司 一种含芴二胺单体、聚酰亚胺薄膜及其制备方法和用途
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
CN119948002A (zh) 2022-07-27 2025-05-06 范徳利亚股份公司 尿石素衍生物和治疗用途
US20240139149A1 (en) 2022-07-27 2024-05-02 Vandria Sa Therapeutic uses of urolithin derivatives
EP4712958A2 (en) 2023-05-18 2026-03-25 Vandria SA Use of urolithin derivatives in the treatment of amyotrophic lateral sclerosis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353717A (zh) * 1999-05-04 2002-06-12 莱加制药公司 四环黄体酮受体调节剂化合物及其方法
WO2004076438A2 (de) * 2003-02-25 2004-09-10 Merck Patent Gmbh Benzochromenderivate
WO2007075884A2 (en) * 2005-12-21 2007-07-05 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CN103370310A (zh) * 2011-02-09 2013-10-23 参天制药株式会社 3-羟基-6H-苯并[c]色烯-6-酮衍生物及其制备方法
US20180256538A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Method for improving mitophagy in subjects
WO2019222146A1 (en) * 2018-05-15 2019-11-21 University Of Louisville Research Foundation, Inc. Urolithin a and derivatives thereof for use in therapy
CN110862368A (zh) * 2019-11-25 2020-03-06 浙江工业大学 一种苯并香豆素类化合物的光催化氧化合成方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G. S. POPE: "Isolation of Two Benzocoumarins from \'Clover Stone\'a Type of Renal Calculus Found in Sheep", BIOCHEMICAL JOURNAL, vol. 93, no. 3, 1 December 1964 (1964-12-01), pages 474 - 477 *
G. W. K. CAVILL，等: "Dibenxo[b, d]pyrans and Related Products", JOURNAL OF THE CHEMICAL SOCIETY, 31 December 1958 (1958-12-31), pages 1544 - 1549 *
KAZUHIRO KUDO，等: "Scalable Synthesis of 8‑Amino-3-hydroxy‑6H‑benzo[c]chromen-6-one: Key Intermediate for SEGRA via the Hurtley Reaction", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 19, no. 1, 11 December 2014 (2014-12-11), pages 309 - 314 *
XIANG-ZHANG TAO，等: "Electrochemical C@O Bond Formation: Facile Access to Aromatic Lactones", CHEM. EUR. J., vol. 24, no. 27, 11 May 2018 (2018-05-11), pages 6932 - 6935 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116670144A (zh) * 2020-12-31 2023-08-29 南京再明医药有限公司 三环类化合物及用途
CN119504692A (zh) * 2024-11-21 2025-02-25 常州大学 磷酸二酯酶2抑制剂的3,8-二羟基-6H-苯并[c]色烯-6-酮类8位羟基醚化衍生物及其应用

Also Published As

Publication number Publication date
US12351567B2 (en) 2025-07-08
MX2023008677A (es) 2023-10-03
JP2024503753A (ja) 2024-01-26
US20240158364A1 (en) 2024-05-16
AU2022212883A1 (en) 2023-08-17
WO2022162471A1 (en) 2022-08-04
KR20230153533A (ko) 2023-11-06
IL304680A (en) 2023-09-01
US12473269B2 (en) 2025-11-18
AU2022212883A9 (en) 2024-10-17
EP4284781A1 (en) 2023-12-06
US12358884B2 (en) 2025-07-15
US20240158365A1 (en) 2024-05-16
US20220259173A1 (en) 2022-08-18
BR112023014973A2 (pt) 2023-11-07
CA3206062A1 (en) 2022-08-04
US20240158363A1 (en) 2024-05-16
US11820751B2 (en) 2023-11-21

Similar Documents

Publication Publication Date Title
CN117015530A (zh) 尿石素衍生物及其使用方法
WO2021190467A1 (zh) 含螺环的喹唑啉化合物
WO2021129820A1 (zh) 含螺环的喹唑啉化合物
EP4144732A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
TWI828712B (zh) 作為ｔｒｋ抑制劑的雜環化合物
CN118791505A (zh) 一种含肟结构的杂环化合物及其制备方法与用途
CN106749513A (zh) 基于vhl配体诱导bet降解的双功能分子及其制备和应用
CN113518779B (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
CN121620366A (zh) 尿石素衍生物在肌萎缩性侧索硬化症的治疗中的用途
EP4378943A1 (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN116390728A (zh) 喹唑啉衍生物及其制备方法和用途
WO2022012593A1 (zh) 5，6-二氢吡嗪并[2，3-c]异喹啉化合物
WO2021254389A1 (zh) 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物
CN115867542B (zh) 新型苯并咪唑化合物
CN115433173B (zh) 一类喹喔啉衍生物及其制备和用途
WO2022228512A1 (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物
CN113754659A (zh) 含螺环的喹唑啉化合物
WO2025091010A1 (en) Organic compounds
CN119371432A (zh) α-倒捻子素衍生物及其制备方法与应用
EP4455139A1 (en) Compound as fak inhibitor and use thereof
HK40090213A (en) Benzothiazolyl biaryl compound, and preparation method and use
WO2021244505A1 (zh) 新型吡嗪化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination